spironolactone has been researched along with Interstitial Nephritis in 5 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
| Excerpt | Relevance | Reference |
|---|---|---|
| " However, eplerenone inhibited the development of renal fibrosis, inflammation (macrophage and monocyte infiltration), interstitial cell proliferation, and activation of interstitial cells (α-SMA expression)." | 7.79 | Eplerenone-mediated aldosterone blockade prevents renal fibrosis by reducing renal inflammation, interstitial cell proliferation and oxidative stress. ( Chen, H; Liu, Y; Shao, Y; Sun, F; Yoshimura, A; Zhong, X, 2013) |
| " However, eplerenone inhibited the development of renal fibrosis, inflammation (macrophage and monocyte infiltration), interstitial cell proliferation, and activation of interstitial cells (α-SMA expression)." | 3.79 | Eplerenone-mediated aldosterone blockade prevents renal fibrosis by reducing renal inflammation, interstitial cell proliferation and oxidative stress. ( Chen, H; Liu, Y; Shao, Y; Sun, F; Yoshimura, A; Zhong, X, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nielsen, FT | 1 |
| Jensen, BL | 1 |
| Hansen, PB | 1 |
| Marcussen, N | 1 |
| Bie, P | 1 |
| Chen, H | 1 |
| Sun, F | 1 |
| Zhong, X | 1 |
| Shao, Y | 1 |
| Yoshimura, A | 1 |
| Liu, Y | 1 |
| Iwazu, Y | 2 |
| Muto, S | 2 |
| Hirahara, I | 1 |
| Fujisawa, G | 2 |
| Takeda, S | 1 |
| Kusano, E | 2 |
| Tylicki, L | 1 |
| Rutkowski, P | 1 |
| Renke, M | 1 |
| Rutkowski, B | 1 |
| Nakazawa, E | 1 |
| Okada, K | 1 |
| Ishibashi, S | 1 |
1 trial available for spironolactone and Interstitial Nephritis
| Article | Year |
|---|---|
Addition of aldosterone receptor blocker to dual renin-angiotensin-aldosterone blockade leads to limitation of tubulointerstitial injury of kidney.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; B | 2007 |
4 other studies available for spironolactone and Interstitial Nephritis
| Article | Year |
|---|---|
The mineralocorticoid receptor antagonist eplerenone reduces renal interstitial fibrosis after long-term cyclosporine treatment in rat: antagonizing cyclosporine nephrotoxicity.
Topics: Animals; Cyclosporine; Drug Interactions; Eplerenone; Fibrosis; Immunosuppressive Agents; Kidney; Lo | 2013 |
Eplerenone-mediated aldosterone blockade prevents renal fibrosis by reducing renal inflammation, interstitial cell proliferation and oxidative stress.
Topics: Animals; Cell Proliferation; Disease Models, Animal; Eplerenone; Fibrosis; Inflammation; Male; Miner | 2013 |
Matrix metalloproteinase 2 induces epithelial-mesenchymal transition in proximal tubules from the luminal side and progresses fibrosis in mineralocorticoid/salt-induced hypertensive rats.
Topics: Animals; Collagen; Desoxycorticosterone; Disease Models, Animal; Disease Progression; Drug Therapy, | 2011 |
Spironolactone suppresses peritubular capillary loss and prevents deoxycorticosterone acetate/salt-induced tubulointerstitial fibrosis.
Topics: Animals; Apoptosis; Capillaries; Connective Tissue Growth Factor; Desoxycorticosterone; Endothelium, | 2008 |